- Home
- PHAR vs ORIC Comparison
PHAR vs ORIC Comparison
Compare PHAR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ORIC
- Stock Information
- Founded
- PHAR 1988
- ORIC 2014
- Country
- PHAR Netherlands
- ORIC United States
- Employees
- PHAR N/A
- ORIC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- ORIC Health Care
- Exchange
- PHAR Nasdaq
- ORIC Nasdaq
- Market Cap
- PHAR 718.1M
- ORIC 362.9M
- IPO Year
- PHAR N/A
- ORIC 2020
- Fundamental
- Price
- PHAR $10.27
- ORIC $10.50
- Analyst Decision
- PHAR Strong Buy
- ORIC Strong Buy
- Analyst Count
- PHAR 3
- ORIC 8
- Target Price
- PHAR $30.00
- ORIC $18.83
- AVG Volume (30 Days)
- PHAR 4.3K
- ORIC 1.1M
- Earning Date
- PHAR 07-31-2025
- ORIC 08-11-2025
- Dividend Yield
- PHAR N/A
- ORIC N/A
- EPS Growth
- PHAR N/A
- ORIC N/A
- EPS
- PHAR N/A
- ORIC N/A
- Revenue
- PHAR $320,708,000.00
- ORIC N/A
- Revenue This Year
- PHAR $13.31
- ORIC N/A
- Revenue Next Year
- PHAR $7.68
- ORIC N/A
- P/E Ratio
- PHAR N/A
- ORIC N/A
- Revenue Growth
- PHAR 24.13
- ORIC N/A
- 52 Week Low
- PHAR $6.65
- ORIC $3.90
- 52 Week High
- PHAR $12.61
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- PHAR 49.06
- ORIC 70.83
- Support Level
- PHAR $10.46
- ORIC $9.80
- Resistance Level
- PHAR $11.49
- ORIC $11.19
- Average True Range (ATR)
- PHAR 0.34
- ORIC 0.61
- MACD
- PHAR -0.12
- ORIC -0.04
- Stochastic Oscillator
- PHAR 31.46
- ORIC 81.20
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.